Dados B3 › MGEL4 × VALE3
MGEL4 × VALE3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | MGEL4 | VALE3 | year |
|---|---|---|---|
| ROE | 202.1% | 7.1% | 2025 |
| ROIC | 12.3% | 6.6%! | 2025 |
| ROA | 6.6% | 2.4% | 2025 |
| Gross margin | 12.7% | 35.0% | 2025 |
| EBIT margin | 7.0% | 15.0% | 2025 |
| Net margin | 4.5% | 5.5% | 2025 |
| Net debt/EBITDA | 5.18x | 1.25x | 2025 |
| Current ratio | 0.46x | 1.15x | 2025 |
| Revenue growth (1y) | 12.2% | 3.7% | 2025 |
| Revenue growth (5y CAGR) | 14.2% | 0.7% | 2025 |
| Piotroski F-Score | 8/9 | 6/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | MGEL4 | VALE3 | year |
|---|---|---|---|
| P/E | 0.76x | 24.49x | 2025 |
| P/B | 0.78x | 1.84x | 2025 |
| EV/EBITDA | 5.57x | 8.12x | 2025 |
| FCF yield | 234.3% | 4.5% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-09 14:21 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.